อภิธานศัพท์เภสัชวิทยา

Area Under the Curve (AUC) (AUC)

Pharmacokinetics

Abbreviated New Drug Application (ANDA) (ANDA)

Clinical

Adverse Drug Reaction (ADR) (ADR)

Clinical

Accelerated Approval

Regulatory

Absorption Rate Constant (Ka) (Ka)

Pharmacokinetics

Autoinduction

Pharmacokinetics

Allosteric Modulator (PAM/NAM) (PAM/NAM)

Pharmacodynamics

Amorphous Solid

Chemistry

Adverse Event (AE) (AE)

Clinical

Antibody-Drug Conjugate (ADC) (ADC)

Research

ABC Transporter Superfamily (ABC) (ABC)

Transporters

ATC Classification (ATC) (ATC)

General

Angiotensin-Converting Enzyme (ACE) (ACE)

Targets & Receptors

Antimetabolite

Immunopharmacology

Anaphylaxis

Immunopharmacology

Autoimmune Disease Therapy

Immunopharmacology

ADMET Prediction (ADMET) (ADMET)

Computational Pharmacology

Agonist

Pharmacodynamics

ADME (ADME) (ADME)

Chemistry

Antagonist

Pharmacodynamics

Bioavailability (F) (F)

Pharmacokinetics

Breakthrough Therapy Designation (BTD) (BTD)

Regulatory

Biologics License Application (BLA) (BLA)

Research

Biosimilar

Research

Bioequivalence (BE) (BE)

Clinical

Blinding

Clinical

BCRP (BCRP) (BCRP)

Transporters

BSEP (BSEP) (BSEP)

Transporters

Bioisostere

Chemistry

Biologic Response Modifier (BRM) (BRM)

Immunopharmacology

Black Box Warning (BBW) (BBW)

Regulatory

Binding Free Energy (delta-G) (delta-G)

Computational Pharmacology

Steady State (Css) (Css)

Pharmacokinetics

Selectivity

Pharmacodynamics

SMILES (SMILES) (SMILES)

Chemistry

Salt Form

Chemistry

Structure-Activity Relationship (SAR) (SAR)

Research

Spare Receptors

Pharmacodynamics

Signal Transduction

Pharmacodynamics

Second Messenger

Pharmacodynamics

Stereoisomer

Chemistry

Solubility

Chemistry

Salt Selection

Chemistry

Serious Adverse Event (SAE) (SAE)

Clinical

Surrogate Endpoint

Clinical

Systems Pharmacology (QSP) (QSP)

Computational Pharmacology

Inverse Agonist

Pharmacodynamics

InChI (InChI) (InChI)

Chemistry

IUPAC Nomenclature (IUPAC) (IUPAC)

Chemistry

International Council for Harmonisation (ICH) (ICH)

Regulatory

Investigational New Drug Application (IND) (IND)

Regulatory

Irreversible Antagonist

Pharmacodynamics

Immunostimulant

Immunopharmacology

Intrinsic Activity (alpha) (alpha)

Pharmacodynamics

Informed Consent (IC) (IC)

Clinical

Intention-to-Treat Analysis (ITT) (ITT)

Clinical

International Nonproprietary Name (INN) (INN)

General

IND-Enabling Studies

Research

Immunotoxicity

Toxicology

Immunosuppressant

Immunopharmacology

Interleukin (IL) (IL)

Immunopharmacology

Ion Channel

Targets & Receptors

Immunoglobulin Therapy (IVIG) (IVIG)

Immunopharmacology

Half Maximal Effective Concentration (EC50) (EC50)

Pharmacodynamics

Half Maximal Inhibitory Concentration (IC50) (IC50)

Pharmacodynamics

High-Throughput Screening (HTS) (HTS)

Research

Hepatic Clearance (CLh) (CLh)

Pharmacokinetics

Henderson-Hasselbalch Equation

Chemistry

Hydrogen Bond (H-bond) (H-bond)

Chemistry

Hydrophobicity

Chemistry

Hepatotoxicity

Toxicology

Hit-to-Lead (H2L) (H2L)

Research

Half-Life (t1/2) (t1/2)

Pharmacokinetics

HMG-CoA Reductase (HMGCR) (HMGCR)

Targets & Receptors

Hypersensitivity Reaction

Immunopharmacology

Homology Modeling

Computational Pharmacology

Hepatic Extraction Ratio (ER) (ER)

Pharmacokinetics

Efficacy (Emax) (Emax)

Pharmacodynamics

European Medicines Agency (EMA) (EMA)

Regulatory

Enzyme Induction

Pharmacokinetics

Extraction Ratio (E) (E)

Pharmacokinetics

Enantiomer

Chemistry

Excipient

General

ENT1 (ENT1) (ENT1)

Transporters

Enzyme Target

Targets & Receptors

Enzyme Inhibition

Pharmacokinetics

Enterohepatic Recirculation

Pharmacokinetics

Potency

Pharmacodynamics

Partition Coefficient (LogP) (LogP)

Chemistry

Phase I Clinical Trial

Clinical

Phase III Clinical Trial

Clinical

Pharmacogenomics (PGx) (PGx)

Research

Plasma Protein Binding Displacement

Pharmacokinetics

Population Pharmacokinetics (PopPK) (PopPK)

Pharmacokinetics

Partial Agonist

Pharmacodynamics

Phase II Clinical Trial

Clinical

Phototoxicity

Toxicology

pKa (pKa) (pKa)

Chemistry

Placebo Effect

Clinical

Post-Marketing Surveillance (PMS) (PMS)

Regulatory

Pediatric Exclusivity

Regulatory

Per-Protocol Analysis (PP) (PP)

Clinical

Priority Review

Regulatory

PROTAC (PROTAC) (PROTAC)

Research

Phenotypic Screening

Research

Preclinical Studies

Research

Pharmacovigilance (PV) (PV)

General

P-glycoprotein (P-gp) (P-gp)

Transporters

PEPT1 (PEPT1) (PEPT1)

Transporters

Protease Inhibitor (PI) (PI)

Targets & Receptors

Phosphodiesterase (PDE) (PDE)

Targets & Receptors

Pharmacophore Modeling

Computational Pharmacology

PK/PD Modeling (PK/PD) (PK/PD)

Computational Pharmacology

Polypharmacy

Clinical

Phase IV Clinical Trial

Clinical

Prodrug

Chemistry

Pharmacodynamics (PD) (PD)

Pharmacodynamics

Physiologically Based Pharmacokinetics (PBPK) (PBPK)

Computational Pharmacology

Protein Binding

Pharmacokinetics

Pharmacokinetics (PK) (PK)

Pharmacokinetics

Tachyphylaxis

Pharmacodynamics

Topological Polar Surface Area (TPSA) (TPSA)

Chemistry

Therapeutic Drug Monitoring (TDM) (TDM)

Clinical

Tolerance

Pharmacodynamics

Target Validation

Research

Teratogenicity

Toxicology

Therapeutic Window

Toxicology

Toll-Like Receptor (TLR) (TLR)

Targets & Receptors

Trough Concentration (Cmin) (Cmin)

Pharmacokinetics

Tumor Necrosis Factor (TNF) (TNF)

Immunopharmacology

Therapeutic Index (TI) (TI)

Pharmacodynamics

Time to Maximum Concentration (Tmax) (Tmax)

Pharmacokinetics

Chirality

Chemistry

Cytochrome P450 (CYP450) (CYP450)

Toxicology

Controlled Substance

General

Compartment Model

Pharmacokinetics

Cross-Tolerance

Pharmacodynamics

Competitive Antagonist

Pharmacodynamics

Ceiling Effect

Pharmacodynamics

Crystalline Polymorphism

Chemistry

Co-Crystal

Chemistry

Crossover Design

Clinical

Compassionate Use

Regulatory

CRISPR Drug Discovery (CRISPR) (CRISPR)

Research

Cardiotoxicity

Toxicology

Carcinogenicity

Toxicology

Constitutive Activity

Targets & Receptors

Clearance (CL) (CL)

Pharmacokinetics

Cyclooxygenase (COX) (COX)

Targets & Receptors

Checkpoint Inhibitor (ICI) (ICI)

Immunopharmacology

CAR-T Cell Therapy (CAR-T) (CAR-T)

Immunopharmacology

Cytokine Storm (CRS) (CRS)

Immunopharmacology

Calcineurin Inhibitor (CNI) (CNI)

Immunopharmacology

Complement Inhibitor

Immunopharmacology

Cheminformatics

Computational Pharmacology

Number Needed to Treat (NNT) (NNT)

Clinical

Number Needed to Harm (NNH) (NNH)

Clinical

No Observed Adverse Effect Level (NOAEL) (NOAEL)

Toxicology

Non-Competitive Antagonist

Pharmacodynamics

Nocebo Effect

Clinical

Nuclear Receptor (NR) (NR)

Targets & Receptors

Narrow Therapeutic Index (NTI) (NTI)

General

Network Pharmacology

Computational Pharmacology

Neurotoxicity

Toxicology

New Drug Application (NDA) (NDA)

Clinical

Non-Linear Pharmacokinetics

Pharmacokinetics

Nephrotoxicity

Toxicology

Randomized Controlled Trial (RCT) (RCT)

Clinical

Risk Evaluation and Mitigation Strategy (REMS) (REMS)

Regulatory

Renal Clearance (CLr) (CLr)

Pharmacokinetics

Racemic Mixture

Chemistry

Regulatory Exclusivity

Regulatory

Relative Risk Reduction (RRR) (RRR)

Clinical

Route of Administration

General

Receptor Tyrosine Kinase (RTK) (RTK)

Targets & Receptors

Receptor Downregulation

Targets & Receptors

Receptor Upregulation

Targets & Receptors

Receptor Trafficking

Targets & Receptors

Receptor Dimerization

Targets & Receptors

Receptor Occupancy (RO) (RO)

Pharmacodynamics

Receptor Desensitization

Pharmacodynamics

Drug-Drug Interaction (DDI) (DDI)

Clinical

Drug-Induced Liver Injury (DILI) (DILI)

Toxicology

Defined Daily Dose (DDD) (DDD)

General

Dose Escalation

Clinical

Dose-Limiting Toxicity (DLT) (DLT)

Clinical

Drug Master File (DMF) (DMF)

Regulatory

Drug Candidate

Research

Dose-Response Assessment

Toxicology

Dosage Form

General

Drug Delivery System (DDS) (DDS)

General

De Novo Drug Design

Computational Pharmacology

Drug-Likeness Score

Computational Pharmacology

Dose-Response Curve

Pharmacodynamics

Drug Repurposing

Research

Good Manufacturing Practice (GMP) (GMP)

Regulatory

Good Clinical Practice (GCP) (GCP)

Regulatory

Generic Drug

General

Graded Dose-Response

Pharmacodynamics

Genotoxicity

Toxicology

G-Protein Coupled Receptor (GPCR) (GPCR)

Targets & Receptors

Orphan Drug Designation (ODD) (ODD)

Regulatory

OTC Monograph

Regulatory

Orphan Receptor

Targets & Receptors

OATP1B3 (OATP1B3) (OATP1B3)

Transporters

OAT1 (OAT1) (OAT1)

Transporters

OAT3 (OAT3) (OAT3)

Transporters

OCT1 (OCT1) (OCT1)

Transporters

OCT2 (OCT2) (OCT2)

Transporters

Off-Label Use

Clinical

OATP1B1 (OATP1B1) (OATP1B1)

Transporters

Lead Optimization

Research

Lethal Dose 50 (LD50) (LD50)

Toxicology

Lipinski's Rule of Five (Ro5) (Ro5)

Chemistry

Ligand-Gated Ion Channel (LGIC) (LGIC)

Targets & Receptors

Loading Dose

Pharmacokinetics

Ligand Efficiency (LE) (LE)

Computational Pharmacology

Maximum Tolerated Dose (MTD) (MTD)

Toxicology

Michaelis-Menten Kinetics

Pharmacokinetics

Molecular Weight (MW) (MW)

Chemistry

Metabolite

Chemistry

Margin of Safety (MOS) (MOS)

Toxicology

Medication Adherence

General

Medication Error

General

MRP1 (MRP1) (MRP1)

Transporters

MRP2 (MRP2) (MRP2)

Transporters

MATE1 (MATE1) (MATE1)

Transporters

MATE2-K (MATE2-K) (MATE2-K)

Transporters

Monoclonal Antibody (mAb) (mAb)

Immunopharmacology

mTOR Inhibitor

Immunopharmacology

Molecular Docking

Computational Pharmacology

Molecular Dynamics Simulation (MD) (MD)

Computational Pharmacology

Machine Learning in Drug Discovery (ML) (ML)

Computational Pharmacology

Maximum Plasma Concentration (Cmax) (Cmax)

Pharmacokinetics

Metabolic Ratio (MR) (MR)

Pharmacokinetics

Maintenance Dose

Pharmacokinetics

Quantal Dose-Response

Pharmacodynamics

Quantitative Structure-Activity Relationship (QSAR) (QSAR)

Computational Pharmacology

Washout Period

Clinical

WHO Prequalification (WHO PQ) (WHO PQ)

Regulatory

Fast Track Designation

Regulatory

Fragment-Based Drug Design (FBDD) (FBDD)

Research

Formulation

General

First-Pass Effect

Pharmacokinetics

Flip-Flop Kinetics

Pharmacokinetics

Food and Drug Administration (FDA) (FDA)

Regulatory

Force Field (FF) (FF)

Computational Pharmacology

505(b)(2) Application (505(b)(2)) (505(b)(2))

Regulatory

Volume of Distribution (Vd) (Vd)

Pharmacokinetics

Voltage-Gated Ion Channel (VGIC) (VGIC)

Targets & Receptors

Vaccine Adjuvant

Immunopharmacology

Virtual Screening (VS) (VS)

Computational Pharmacology

Kinase Inhibitor

Targets & Receptors